Bone Biologics Corp Operating Income

Quick Answer

Bone Biologics Corp reported Operating Income of -$3.23 million for fiscal year 2025.

Bone Biologics Corp Operating Income — Annual History

Fiscal Year Operating Income YoY Change
2025 -$3.23M +23.3%
2024 -$4.22M +55.3%
2023 -$9.43M -157.2%
2022 -$3.67M -232.3%
2021 -$1.10M -33.7%
2020 -$825.0K +66.3%
2019 -$2.45M +12.3%
2018 -$2.79M -6.3%
2017 -$2.63M +87.1%
2016 -$20.41M -70.2%
2015 -$12.00M -298.5%
2014 -$3.01M -348.0%
2013 -$672.0K

Quarterly Operating Income

Quarter Ending Operating Income YoY QoQ
September 30, 2025 -$715.3K +24.8% +4.4%
June 30, 2025 -$748.1K +7.6% +28.0%
March 31, 2025 -$1.04M -14.9% -9.2%
September 30, 2024 -$951.0K +54.3% -17.5%
June 30, 2024 -$809.7K +73.4% +10.4%
March 31, 2024 -$903.5K +71.3% +56.6%
September 30, 2023 -$2.08M -70.7% +31.5%
June 30, 2023 -$3.04M -547.7% +3.4%
  • Bone Biologics Corp showed an increase of +23.3% in Operating Income compared to the prior fiscal year.
  • Over the 2013–2025 period, Bone Biologics Corp’s operating income has declined by 381.4% (from -$672.0 thousand to -$3.23 million).
  • The most recent figure is from Bone Biologics Corp’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 2, 2026.
  • All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.

Last verified:

Leave a Comment